Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytomed Therapeutics Limited (GDTC)

Cytomed Therapeutics Limited (GDTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,482
  • Shares Outstanding, K 10,940
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,130 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.70
Trade GDTC with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +2.75%
on 05/03/24
2.25 -8.67%
on 04/22/24
-0.05 (-2.61%)
since 04/03/24
3-Month
1.92 +7.03%
on 02/07/24
3.45 -40.43%
on 02/05/24
-1.45 (-41.41%)
since 02/02/24
52-Week
1.92 +7.03%
on 02/07/24
9.25 -77.78%
on 07/11/23
-1.56 (-43.23%)
since 05/03/23

Most Recent Stories

More News
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration

The global population is rapidly aging. According to the World Population Prospects 2022 published by the United Nations, there were

GDTC : 2.06 (-2.14%)
Singapore’s Journey to Becoming a Biotech Powerhouse

Singapore's Biotech Vision: From 2000 Onwards In 2000, Singapore embarked on an ambitious mission to establish itself as a leading

GDTC : 2.06 (-2.14%)
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

/PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...

GDTC : 2.06 (-2.14%)
Singapore’s Leap into the Future of Cell and Gene Therapies

Singapore is making remarkable progress in the realm of cell and gene therapy (CGT), as evidenced by the inauguration of

GDTC : 2.06 (-2.14%)
CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit

Singapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual Investor...

GDTC : 2.06 (-2.14%)
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

/PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...

GDTC : 2.06 (-2.14%)
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

/PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...

GDTC : 2.06 (-2.14%)
The Dawn of a New Era in Immunotherapy for Cancers: Understanding CytoMed Therapeutics’ (NASDAQ: GDTC) iPSC-Derived Gamma Delta NKT Cell Technology

CytoMed Therapeutics, a NASDAQ-listed company (Stock Symbol: GDTC), is at the forefront of a revolution in cellular therapy for cancers.

GDTC : 2.06 (-2.14%)
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

/PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its...

GDTC : 2.06 (-2.14%)
CytoMed (NASDAQ: GDTC): Revolutionizing Cancer Treatment with Unique CAR-T Cell Technology

Despite the substantial advances in medical technology, cancer remains a formidable foe with an alarming annual growth rate. According to

GDTC : 2.06 (-2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. CytoMed Therapeutics Limited is based in SINGAPORE.

See More

Key Turning Points

3rd Resistance Point 2.24
2nd Resistance Point 2.18
1st Resistance Point 2.12
Last Price 2.06
1st Support Level 2.00
2nd Support Level 1.94
3rd Support Level 1.88

See More

52-Week High 9.25
Fibonacci 61.8% 6.45
Fibonacci 50% 5.59
Fibonacci 38.2% 4.72
Last Price 2.06
52-Week Low 1.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar